Word

AFFILIN

Status

Registered

Status Code

707

Status Date

Tuesday, May 17, 2022

Serial Number

79155885

Registration Number

4838850

Registration Date

Tuesday, October 27, 2015

Mark Type

4

Filing Date

Tuesday, July 29, 2014

Published for Opposition

Tuesday, August 11, 2015

Trademark Owner History

Scil Proteins GmbH - Original Registrant

Classifications

5 [Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; medical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; biochemical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis, except preparations containing theophylline; diagnostic and analytical preparations for medical and veterinary use; biological and chemical diagnostic reagents for medical use]

1 [Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes, including the manufacturing and purification of proteins, polypeptides, chemicals and other substances; diagnostic and analytic preparations for scientific or research use, not for medical or veterinary use; chemical reagents for analysis in laboratories, not for medical or veterinary use; biological tissue cultures for laboratories, not for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes]

42 Scientific and industrial research in particular in the biological, biochemical, diagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological services, namely, scientific research, analysis, testing, in particular in the biological, biochemical, diagnostic and pharmaceutical fields; industrial research and analysis, namely, services in development of biological, biochemical, pharmaceutical and diagnostic products; research for the identification and further development of biological, biochemical, pharmaceutical and diagnostic products

Trademark Events

Dec 8, 2014

New Application Office Supplied Data Entered

Dec 8, 2014

Assigned To Examiner

Dec 8, 2014

Non-Final Action Written

Dec 27, 2014

Refusal Processed By Ib

Jun 10, 2015

Teas Response To Office Action Received

Jun 17, 2015

Assigned To Lie

Dec 4, 2014

Sn Assigned For Sect 66a Appl From Ib

Dec 9, 2014

Non-Final Action (Ib Refusal) Prepared For Review

Dec 10, 2014

Refusal Processed By Mpu

Dec 10, 2014

Non-Final Action Mailed - Refusal Sent To Ib

Dec 12, 2014

Application Filing Receipt Mailed

Jun 24, 2015

Correspondence Received In Law Office

Jun 24, 2015

Teas/Email Correspondence Entered

Jul 6, 2015

Examiners Amendment -Written

Jul 6, 2015

Examiners Amendment E-Mailed

Jul 6, 2015

Notification Of Examiners Amendment E-Mailed

Jul 6, 2015

Examiner's Amendment Entered

Jul 7, 2015

Approved For Pub - Principal Register

Jul 8, 2015

Law Office Publication Review Completed

Aug 5, 2015

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Aug 5, 2015

Notification Of Possible Opposition Sent To Ib

Jan 27, 2016

Final Disposition Notice Created, To Be Sent To Ib

May 12, 2016

Final Disposition Processed

May 12, 2016

Final Disposition Notice Sent To Ib

Jul 22, 2015

Notification Of Notice Of Publication E-Mailed

Aug 11, 2015

Published For Opposition

Aug 11, 2015

Official Gazette Publication Confirmation E-Mailed

Aug 21, 2015

Notification Processed By Ib

Oct 27, 2015

Registered-Principal Register

Jul 15, 2016

Final Decision Transaction Processed By Ib

Oct 27, 2020

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Oct 26, 2021

Teas Section 71 Received

May 10, 2022

Case Assigned To Post Registration Paralegal

May 17, 2022

Registered - Partial Sec 71 Accepted

Jan 17, 2023

Partial Invalidation Of Reg Ext Protection Created

May 17, 2022

Notice Of Acceptance Of Sec. 71 - E-Mailed

Mar 9, 2023

Invalidation Processed

Apr 30, 2023

Partial Invalidation Processed By The Ib

May 24, 2024

International Registration Renewed

Mar 9, 2023

Partial Invalidation Of Reg Ext Protection Sent To Ib